These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 36290817)

  • 1. Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer.
    Poddar A; Rao SR; Prithviraj P; Kannourakis G; Jayachandran A
    Curr Oncol; 2022 Sep; 29(10):6847-6863. PubMed ID: 36290817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
    Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
    J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC).
    Michaels E; Chen N; Nanda R
    Clin Breast Cancer; 2024 Jun; 24(4):263-270. PubMed ID: 38582617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Immunotherapy in Triple-Negative Breast Cancer.
    Keenan TE; Tolaney SM
    J Natl Compr Canc Netw; 2020 Apr; 18(4):479-489. PubMed ID: 32259782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
    Heeke AL; Tan AR
    Cancer Metastasis Rev; 2021 Jun; 40(2):537-547. PubMed ID: 34101053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer.
    Steiner M; Tan AR
    Clin Adv Hematol Oncol; 2021 May; 19(5):305-315. PubMed ID: 33989278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
    Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
    Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
    Hall PE; Schmid P
    Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
    Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Varma R; Wright M; Abraham J; Kruse M
    Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
    He R; Yuan X; Chen Z; Zheng Y
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109444. PubMed ID: 36402069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
    Mohamed A; Kruse M; Tran J
    Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
    Howard FM; Villamar D; He G; Pearson AT; Nanda R
    Expert Opin Investig Drugs; 2022 Jun; 31(6):531-548. PubMed ID: 34569400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT1: A key drug target in triple-negative breast cancer.
    Wong KK
    Semin Cancer Biol; 2021 Jul; 72():198-213. PubMed ID: 32461152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single peptides and combination modalities for triple negative breast cancer.
    Razazan A; Behravan J
    J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer.
    Michel LL; von Au A; Mavratzas A; Smetanay K; Schütz F; Schneeweiss A
    Target Oncol; 2020 Aug; 15(4):415-428. PubMed ID: 32514907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
    Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer.
    Jarroudi OA; Bairi KE; Curigliano G; Afqir S
    Cancer Treat Res; 2023; 188():29-62. PubMed ID: 38175341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific Antibodies for Triple Negative Breast Cancer.
    Dees S; Ganesan R; Singh S; Grewal IS
    Trends Cancer; 2021 Feb; 7(2):162-173. PubMed ID: 33041246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.